CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.407
EU - Europa 5.625
AS - Asia 4.468
SA - Sud America 570
AF - Africa 109
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.192
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.243
RU - Federazione Russa 2.030
SG - Singapore 1.758
CN - Cina 1.294
GB - Regno Unito 1.279
IT - Italia 522
BR - Brasile 468
VN - Vietnam 431
HK - Hong Kong 377
FR - Francia 323
SE - Svezia 322
IE - Irlanda 296
DE - Germania 278
FI - Finlandia 240
KR - Corea 151
CA - Canada 96
UA - Ucraina 83
IN - India 79
TR - Turchia 58
BD - Bangladesh 55
JP - Giappone 54
MX - Messico 48
NL - Olanda 46
AR - Argentina 42
PL - Polonia 38
ID - Indonesia 35
ES - Italia 32
IQ - Iraq 30
BE - Belgio 29
NG - Nigeria 26
ZA - Sudafrica 26
IR - Iran 23
PK - Pakistan 20
EC - Ecuador 13
SA - Arabia Saudita 13
AT - Austria 12
CH - Svizzera 11
LT - Lituania 11
MA - Marocco 11
PH - Filippine 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
VE - Venezuela 10
GR - Grecia 9
CO - Colombia 8
EG - Egitto 8
UY - Uruguay 8
BY - Bielorussia 7
CL - Cile 7
HR - Croazia 7
JO - Giordania 7
PE - Perù 7
PT - Portogallo 7
AU - Australia 6
AZ - Azerbaigian 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AL - Albania 5
DZ - Algeria 5
KE - Kenya 5
RO - Romania 5
TW - Taiwan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
JM - Giamaica 4
KW - Kuwait 4
LV - Lettonia 4
PA - Panama 4
BJ - Benin 3
CZ - Repubblica Ceca 3
EU - Europa 3
HN - Honduras 3
IL - Israele 3
KZ - Kazakistan 3
LU - Lussemburgo 3
NP - Nepal 3
OM - Oman 3
SN - Senegal 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CM - Camerun 2
CR - Costa Rica 2
CY - Cipro 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
QA - Qatar 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AM - Armenia 1
BO - Bolivia 1
BS - Bahamas 1
Totale 17.171
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Singapore 925
Moscow 701
Ashburn 653
Chandler 644
Dallas 630
Jacksonville 564
San Jose 547
Woodbridge 408
Hong Kong 362
Dublin 293
Ann Arbor 281
Verona 260
Beijing 240
Houston 206
The Dalles 177
Council Bluffs 135
Ho Chi Minh City 134
New York 113
Lawrence 106
Princeton 106
Wilmington 100
Los Angeles 95
Jinan 92
Hanoi 84
Nanjing 80
Shenyang 65
Buffalo 64
Tianjin 64
Helsinki 63
Tokyo 50
Hebei 49
São Paulo 48
Santa Clara 47
Changsha 43
Columbus 42
Munich 41
Sindelfingen 39
Seoul 37
Zhengzhou 37
Dong Ket 35
Orem 35
Milan 34
Chennai 33
London 33
Seattle 32
Boardman 31
Montreal 30
Warsaw 30
Brussels 29
Redondo Beach 29
Guangzhou 28
Jakarta 27
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Abuja 23
Denver 23
Redwood City 23
San Francisco 23
Atlanta 22
Frankfurt am Main 22
Taizhou 22
Johannesburg 21
Taiyuan 21
Brooklyn 20
Stockholm 20
Turku 20
Da Nang 19
Nanchang 19
Amsterdam 18
Norwalk 18
Boston 17
Lancaster 17
Paris 17
Bologna 16
Chicago 16
Fuzhou 16
Rio de Janeiro 15
Redmond 14
Toronto 14
Falkenstein 13
Manchester 13
Montréal 13
Padova 13
Shanghai 13
Mexico City 12
Nuremberg 12
Poplar 12
Rome 12
Tashkent 11
Barnet 10
Biên Hòa 10
Haiphong 10
Belo Horizonte 9
Brasília 9
Curitiba 9
Lappeenranta 9
Phoenix 9
Totale 10.877
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 288
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 273
Immunotoxins and other conjugates: preparation and general characteristics. 256
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 248
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 238
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 238
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 235
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 231
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 229
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 218
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 216
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 216
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 215
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 212
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 210
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 210
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 208
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 206
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 204
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 202
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 197
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 195
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 194
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 194
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 193
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 191
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 185
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 185
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 184
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 184
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 183
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 181
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 179
N-terminal deletion affetcs catalytic activity of saporin toxin. 178
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 178
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 178
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 177
Cloning and characterisation of canine prostate-specific membrane antigen 176
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 176
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 175
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 174
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 174
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 172
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 172
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 171
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 171
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 169
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 166
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 165
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 165
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 165
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 164
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 160
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 157
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 156
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 156
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 153
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 152
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 152
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 150
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 148
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 143
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 143
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 140
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 140
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 138
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 135
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 132
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 131
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 130
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 128
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 128
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 127
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 126
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 126
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 126
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 125
Effect of therapeutic macromolecules in spheroids 124
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 124
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 123
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 123
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 122
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 119
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 118
Ribosome-inactivating protein-containing conjugates for therapeutic use 118
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children 115
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 114
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 112
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 111
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 111
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 110
PSMA as a new target for anti-vascular therapy. Development of an in vitro model of PSMA positive endothelial cells. 108
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 108
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 105
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 103
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 103
Targeting prostate cancer cells with D2B-gold Nanoparticles 103
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 102
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 101
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 100
Totale 16.343
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.138
article - articoli 41.323
book - libri 0
conference - conferenze 12.952
curatela - curatele 0
other - altro 0
patent - brevetti 990
selected - selezionate 0
volume - volumi 873
Totale 112.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202166 0 0 0 0 0 0 0 0 0 0 0 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20267.231 506 447 618 1.103 1.808 498 723 345 508 408 102 165
Totale 17.309